A need for revision of WHO classification of all ductal adenocarcinomas and subtypes of IPMN is suggested, also taking validated and recommended diagnostic use of MUC1 antibody, which recognizes fully glycosylated MUC1, into consideration [125]. Here, MUC1 is linked to pancreatic intraductal papillary-mucinous neoplasm.